Filing Flows

Filing Flows › Caris Life Sciences (CAI) › Next earnings date

Caris Life Sciences (CAI) earnings: beat the estimate

Caris Life Sciences (CAI) reported on Nov 4, 2026 and beat the EPS estimate: $0.05 against $0.02 (+148.5%). Revenue was $275M for Q3 2026, +27% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+148.5% vs estimate
Beat rate80%

The last report

Caris Life Sciences reported revenue of $275M for the third quarter 2026 (+27% Y/Y), net earnings $15.2M: Molecular Profiling Services $263M, Pharma Research and Development Services $12.7M. How it makes money → · Every quarter →

Caris Life Sciences: EPS against the estimate, last 5 reportsCaris Life Sciences: EPS against the estimate, last 5 reportsEstimateReported−$0.14$0.08Nov 25$0.10$0.28Feb 26−$0.02$0.00May 26$0.01$0.00Aug 26$0.02$0.05Nov 26
Latest (Nov 26): Estimate $0.02, Reported $0.05.

Caris Life Sciences' latest quarter

Caris Life Sciences, Q3 2026: revenue $275M (+27% year over year), operating margin 7.0%, net earnings $15.2M, operating cash flow −$22.2M. The chart follows the revenue to costs, profit and cash.

Questions

Did Caris Life Sciences beat earnings?

Caris Life Sciences (CAI) reported on Nov 4, 2026 and beat the EPS estimate: $0.05 against $0.02 (+148.5%).

When does CAI report earnings?

The next date is not set yet.

Does Caris Life Sciences usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.